Research field (3)：
Pharmaceuticals - chemistry and drug development
, Pharmaceuticals - chemistry and drug development
, Pharmaceuticals - chemistry and drug development
Research keywords (2)：
Motilin
, ケミカルプロテオミクス
Papers (29)：
Kazuo Fujihara, Satoshi Hattori, Ingo Kleiter, Michael Levy, Yuya Matsuda, Asako Mitsutake, Masayuki Haramura, Jacqueline Palace, Takashi Yamamura. Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. Journal of the neurological sciences. 2021. 428. 117546-117546
Kazuo Fujihara, Jeffrey L. Bennett, Jerome de Seze, Masayuki Haramura, Ingo Kleiter, Brian G. Weinshenker, Delene Kang, Tabasum Mughal, Takashi Yamamura. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2020. 7. 5
Janine Beekman, Aysha Keisler, Omar Pedraza, Masayuki Haramura, Athos Gianella-Borradori, Eliezer Katz, John N. Ratchford, Gerard Barron, Lawrence J. Cook, Jacinta M. Behne, et al. Neuromyelitis optica spectrum disorder Patient experience and quality of life. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2019. 6. 4. e580
Miyuki Mabuchi, Tadashi Shimizu, Masayuki Haramura, Akito Tanaka. Identification and purification of target protein using affinity resin bearing a photo-labile linker. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2015. 25. 16. 3373-3377
Kohji Nagano, Takashi Shinkawa, Kuniyasu Kato, Noriyuki Inomata, Nami Yabuki, Masayuki Haramura. Distinct cell surface proteome profiling by biotin labeling and glycoprotein capturing. JOURNAL OF PROTEOMICS. 2011. 74. 10. 1985-1993
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching-Piao Tsai, Albert Saiz, Masayuki Haramura, et al. Efficacy of Satralizumab (SA237) in Subgroups of Patients in SakuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). MULTIPLE SCLEROSIS JOURNAL. 2020. 26. 9. NP39-NP39
荒木 学, 藤原 一男, 原村 昌幸, 寺田 悠介, 河田 祐一, 山村 隆, the SAkuraSky and SAkuraStar study authors and investigators. MS/NMO1 Satralizumabの有効性と安全性 NMOSD患者に対する二重盲検プラセボ対照P3研究(MS/NMO 1 Efficacy and safety of satralizumab: double-blind placebo-controlled P3 studies in NMOSD patients). 神経免疫学. 2019. 24. 1. 105-105
Takashi Yamamura, Ingo Kleiter, Kazuo Fujihara, Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska-Pniewska, Francesco Patti, Ching Piao Tsai, Albert Saiz, Masayuki Haramura, et al. Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD). NEUROLOGY. 2019. 92. 15
NAGANO Kohji, INOMATA Noriyuki, SHINKAWA Takashi, KONDOH Osamu, HATTORI Kazuo, MASUBUCHI Miyako, NIIZUMA Satoshi, SAITO Hidemi, NAKANISHI Yoshito, ISHII Nobuya, et al. Identification of Binding Proteins Responsible for Antitumor Activity of Novel Small Molecule CH4938056 Using Chemical Proteomics. 2012. 2011. 81-82
Haramura Masayuki, Ashihara Motooki, Inomata Noriyuki, Kato Kuniyasu, Shinkawa Takashi, Nagano Kohji, Yabuki Nami, Mutoh Hironori. Proteomics for drug target discovery and mode-of-action analysis of drug candidates. Abstracts for Annual Meeting of Japanese Proteomics Society. 2012. 2012. 0. 39-39
